Benjamin Burck
Benjamin Burck
Mark Lakeram
Mark Lakeram
Olaf Pongs
Olaf Pongs
Catherine Rees
Catherine Rees
Katrina Pollock,Peter Openshaw
Katrina Pollock
Leonard Bielory
Leonard Bielory
P Norman
P Norman
Risedronate (NE-58095) is a third generation bisphosphonate bone-resorption inhibitor and osteogenesis stimulator under development by Norwich-Eaton (a subsidiary of Procter and Gamble) for the potential treatment of various bone diseases i...
C E Heading
C E Heading
AD-5423, a D(2)/5-HT2 antagonist, is in phase II clinical trials by Dainippon for the treatment of schizophrenia and other psychoses. In a phase I study of AD-5423 in eight healthy volunteers, it appeared to be well-tolerated and failed to ...
X Wang
X Wang
NicOx is developing nitroflurbiprofen (HCT-1026) as a non-steroidal anti-inflammatory drug (NSAID) which has the ability to release nitric oxide. It has completed phase I clinical trials as a potential treatment for inflammation and rheumat...